



PATENT Ifw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
STROBEL, et al.

Examiner: Powers, F.

Art Unit: 1626

Application No.: **10/632,083**

Filed: **July 31, 2003**

Title: **ACYLATED, HETEROARYL-CONDENSED
CYCLOALKENYLAMINES AND THEIR USE
AS PHARMACEUTICALS**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 15, 2005
Date of Deposit
Paul Irvine
Paul Irvine

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98


Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.


- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,



Joseph D. Rossi, Reg. No. 47,038
Attorney for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3410
Telefax (908) 231-2626
Aventis Docket No. DEAV2002/0057 US NP



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/632,083
Filing Date	07-31-2003
First Named Inventor	STROBEL
Group Art Unit	1626
Examiner Name	Powers, F.
Attorney Docket Number	DEAV2002/0057 - US - NP

Sheet	1	of	4
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials [*]	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		20030055093		STROBEL	03-20-2003	
		20030022935		STROBEL	01-30-2003	
		20040225013		STROBEL	11-11-2004	
		20030055087		SHINKAI, et al.	03-20-2003	
		20040142976		KAWAI, et al.	07-22-2004	
		5,527,815		TOMIYAMA, et al.	06-18-1996	
		5,753,662		PEGLION, et al.	05-19-1998	
		6,048,880		KAWAI, et al.	04-11-2000	
		6,258,829		TAKAHASHI, et al.	07-10-2001	
		6,278,027		TOMIYAMA, et al.	08-21-2001	
		6,410,561		SHINKAI, et al.	06-25-2002	
		6,696,470		KAWAI, et al.	02-24-2004	
		6,759,412		STROBEL	07-06-2004	
		6,617,359		STROBEL	09-09-2003	
		6,812,253		STROBEL	11-02-2004	
		20050054729		STROBEL	03-10-2005	

FOREIGN PATENT DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		CA	2,151,443		TOMIYAMA, et al.	06-09-1995		
		WO	00/03746		LIAO	01-27-2000		
		WO	01/68652		ANDERSON, et al.	09-20-2001		
		WO	99/47153		LIAO	09-23-1999		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/632,083
				Filing Date	07-31-2003
				First Named Inventor	STROBEL
				Group Art Unit	1626
				Examiner Name	Powers, F.
Sheet	2	of	4	Attorney Docket Number	DEAV2002/0057 - US - NP

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BIANCHI, et al., Regioselectivity in the Reactions of Benzonitrile N-Phenyl-Imide and Some Benzonitrile N-Oxides with α,β-Unsaturated Ketones., J. Chem. Res, Synop. (1981) 6-7	
		BINDER, et al., A Facile Route to Functionalized Cyclopenta [b] thiophenones Based on the Structure of the Selective COX-2 Inhibitor Flosulide, Monatsh. Chem 129, (1998), 887-896	
		CAPRATHE, et al., Dopamine Autoreceptor Agonists as Potential Antipsychotics. 3. 1 6-Propyl-4,5,6,7,8-hexahydrothiazolo [4,5-f] quinolin-2-amine, J. Med. Chem. 34, (1991), 2736-2746	
		DAMMERTZ, et al., Synthese Von 6,7,8,9-Tetrahydro-5H-cyclohepta[b] pyridin-5-on, Arch. Pharm. 310 (1977), 172-176	
		ENDRES, et al., Stroke Protection By 3-Hydroxy-3-Methylglutaryl (HMG) - CoA Reductase Inhibitors Medicated By Endothelial Nitric Oxide Synthase, Proc. Natl. Acad. Sci. USA, 95 (1998) 8880-8885	
		HICKS, et al., The Synthesis And Photochemical Behaviour Of Some Annelated Tropones, J. Chem. Soc. Perkin Trans. 1, (1984) 2297-2304	
		HOFFMAN, et al., Synthesis Of 3-Nitro-5-Acylpyridines By Condensation Of Sodium Nitromalonadehyde/Tosyl Chloride With 2-Amino-1-Acyl Olefins. Evidence For the Intermediacy of 3-Chloro-2-Nitroacrolein, J. Org. Chem. 49 (1984), 193-195	
		HUANG, et al., The Improved Preparation Of 7,8-Dihydro-Quinoline-5(6H)-One and 6,7-Dihydro-5H-1-Pyridin-5-One, Synth. Commun. 28 (1998), 1197-1200	
		JONES, et al., Synthesis Of 4H-Cyclohepta [b] thiophen-4-ones, 4H-Cyclohepta [b] furan-4-one, and 9H-Cyclohepta[b] pyridin-9-one, J. Chem. Soc., Perkin Trans., 1, (1973), 968-972	
		KOEHLER, et al., Potential Anticancer Agents IX. Tetrahydroquinazoline Analogs Of Tetrahydrofolic Acid. I, J. Am. Chem. Soc. 80 (1958) 5779-5785	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/632,083
				Filing Date	07-31-2003
				First Named Inventor	STROBEL
				Group Art Unit	1626
				Examiner Name	Powers, F.
Sheet	3	of	4	Attorney Docket Number	DEAV2002/0057 - US - NP

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LI, et al., Activation Of Protein Kinase Ca and/or e Enhances Transcription of the Human Endothelial Nitric Oxide Synthase Gene, Mol. Pharmacol. 53 (1998) 630-637	
		MACDOWELL, et al., The Use Of 2,5-Dichlorothiophene In The Synthesis Of 3,4-Disubstituted Thiophenes, J. Org. Chem. Soc. 32 (1967) 1226-1229	
		MOROI, et al., Interaction of Genetic Deficiency of Endothelial Nitric Oxide, Gender, and Pregnancy in Vascular Response to Injury in Mice, J. Clin. Invest., 101 (1998) 1225-1232	
		MURARO, et al., Heterocycles sulfures condensés. - Synthèse et dechloration de dichloro-1,3 thieno (c) cyclonones., Bull. Soc. Chim. Fr., Pt. 2, (1973) 335-342	
		MURARO, et al., Recherches dans le domaine des thieno (c) cyclonones., C.R. Acad. Sci., Ser. C, 273 (1971) 1362-1367	
		NAKAYAMA, et al., T-786 - C Mutation in the 5' -Flanking Region of the Endothelial Nitric Oxide Synthase Gene Is Associated With Coronary Spasm, Circulation 99 (1999) 2864-2870	
		NAYYAR, et al., New Approach for the General Synthesis of Oxotetrahydroindoles via Intramolecular Cycloadditions of Azomethine Ylides with Tethered Alkynes, J. Org. Chem. 62 (1997) 982-991	
		RAVINA, et al., Conformationally Constrained Butyrophenones with Mixed Dopaminergic (D2) and Serotonergic (5-HT _{2A} , 5-HT _{2C}) Affinities: Synthesis, Pharmacology, 3D-QSAR, and Molecular Modeling of (Aminoalkyl) benzo- and - thienocycloalkanones as Putative Atypical Antipsychotics, J. Med. Chem. 42 (1999) 2774-2797	
		REIMANN, et al., Regioselektive Synthese von 4-Methyl-1-pyridin-5-on, Pharmazie 50 (1995) 589-592	
		RUANGSIYANAND, et al., Enamine Cyclischer 1,3-Diketone als Ausgangsstoffe für Pyridinringsynthesen, Chem. Ber. 103 (1970) 2403-2410	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/632,083	
			Filing Date	07-31-2003	
			First Named Inventor	STROBEL	
			Group Art Unit	1626	
			Examiner Name	Powers, F.	
Sheet	4	of	4	Attorney Docket Number	DEAV2002/0057 - US - NP

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SCHENONE, et al., Reaction of 2-Dimethylaminomethylene-1,3-diones with Dinucleophiles. I. Synthesis of 1,5-Disubstituted 4-Acylpyrazoles, J. Heterocyclic Chem., 19 (1982) 1355-1361	
		SCHROEDER, et al., Nichtsteroidale Entzündungshemmer. 3. Substituierte Aza-Tetralin - und Aza-indancarbonsauren Mit Antiphlogistischer Wirkung, J. Med. Chem. - Chim. Ther. 14 (1979) 309-315	
		SESSA, et al., Chronic Exercise In Dogs Increases Coronary Vascular Nitric Oxide Production And Endothelial Cell Nitric Oxide Synthase Gene Expression, Circ. Research 74 (1994) 349-353	
		SHIGEKI, et al., 7-Oxocyclopenta[d]Pyrimidine Derivative, esp@cenet database - 12 -Document Bibliography and Abstract	
		TAKESHI, et al., Benzoic Acid Derivative Or Its Salt, esp@cenet database -12 - Document Bibliography and Abstract	
		VARENNE, et al., Percutaneous Gene Therapy Using Recombinant Adenoviruses Encoding Human Herpes Simplex Virus Thymidine Kinase, Human PAI-1, and Human NOS3 in Balloon-Injured Porcine Coronary Arteries, Hum. Gene Ther. 11 (2000) 1329-1339	
		WESTERWELLE, et al., B-Aminoketone als Schlüsselverbindungen zur Synthese von Pyridinen: Ein Neuartiger, Leistungsfähiger Zugang zu Kondensierten Bi- und Terpyridinen, Chem. Ber. 124 (1991) 571-576	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.